REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Protocols
14

Melanotan II Protocol — What Worked For Me

Avery Kim 106·about 1 month ago
After a lot of research and hesitation, I finally started Melanotan II about 6 weeks ago. Here is exactly what I am doing and what I have experienced. Dosage: started at the lower end of the commonly discussed range and stayed there for 2 weeks to assess tolerance. Bumped up to what seems to be the sweet spot by week 3. Administration is subcutaneous with a 29-gauge insulin syringe. Schedule: I dose in the evening, about 30 minutes before bed. I chose this timing because several users reported better sleep with evening dosing, and that has been my experience as well. Sleep latency has decreased noticeably. Side effects: first week I had some mild nausea that resolved on its own. Occasional headache in weeks 2-3 that I managed with extra hydration. Nothing since then. Results so far are encouraging but not dramatic. I think the people who report overnight transformations are either exaggerating or responding unusually well. For me it has been a gradual, steady improvement that became clearly noticeable around week 4-5. I plan to do a full write-up with before and after data when I finish my planned 12-week protocol.

Comments (5)

Rowan Garcia 213·about 1 month ago

One thing I wish more Melanotan II discussions covered is the discontinuation experience. What happens when you stop? In my case, the benefits gradually faded over about 3-4 weeks after stopping. Sleep was the first thing to return to baseline. Recovery improvements lasted a bit longer. Worth knowing for planning protocol duration.

3
Micah Garcia 230·about 1 month ago

Great point about bloodwork. I ran comprehensive panels at baseline, 6 weeks, and 12 weeks during my Melanotan II protocol. The most informative markers for me were inflammatory markers and IGF-1 levels. Would strongly recommend anyone running Melanotan II to invest in proper monitoring.

4
Reign Garcia 247·about 1 month ago

The timeline you describe is spot on with my Melanotan II experience. I also want to emphasize the importance of injection technique. When I switched from 30-gauge to 29-gauge needles and slowed my injection speed, the site irritation essentially disappeared. Small details make a big difference in compliance.

5
Sage Muller 264·about 1 month ago

Following up on my earlier comment about Melanotan II. I am now 4 weeks past the end of my protocol and wanted to report that about 60 percent of the benefits seem to have persisted. Sleep is still better than baseline, recovery is somewhere between pre-protocol and on-protocol levels. Encouraging for the sustainability question.

6
Phoenix Muller 281·about 1 month ago

Great write-up. I have been running a similar Melanotan II protocol and my experience aligns pretty closely with what you described. The sleep improvements were the first thing I noticed too, usually around week 2-3. One thing I would add is that I found keeping injection sites consistent with rotation between 4-5 spots worked better than random placement. Less irritation overall.

2

Sign in to comment.